NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Atrium Therapeutics, Inc. (RNA) Stock Analysis

Atrium Therapeutics, Inc. (RNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RNA

$14.19

−$0.41 (−2.81%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNA with… →

RNA Key Statistics

As of Sep 4, 2026
Trading
Open
$14.51
Previous Close
$14.60
Day's Range
14.01–14.65
52-Week Range
11.13–16.77
Volume
167.80K
Valuation
Market Cap
$242.73M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.77
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.28
Financials (FY)
Revenue (FY)
$18.62M+70.85%
Net Income (FY)
−$76.68M
Profit marginThe share of revenue left as profit after all costs and taxes.
−184.15%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.11M
1-Year Return
−70.72%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
181.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RNA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−80.33%
2025+148.04%
2024 (partial year)−6.34%

As of September 4, 2026.

RNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$18.62M−$76.68M−411.9%
2024$10.90M−$25.12M−230.5%
2023$9.76M−$6.39M−65.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$18.62M—−$76.81M−$76.68M−411.9%
2024$10.90M—−$13.22M−$25.12M−230.5%
2023$9.76M—−$6.39M−$6.39M−65.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RNA Valuation vs Biotechnology Median

Median of 656 stocks
MetricRNABiotechnology medianvs median
P/S ratio6.7715.2656% below
Profit margin−184.15%0.00%184.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Atrium Therapeutics, Inc. (RNA) carries a market capitalisation of $242.73M. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for RNA is $14.19, dated September 4, 2026. That is −$0.41 (−2.81%) against the previous close. The 52-week range on file runs from $11.13 to $16.77. The latest close sits 27.49% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $18.62M. Against the prior fiscal year total of $10.90M, that is a change of +70.85%. The same year closed with a net loss of $76.68M. The reported profit margin is −184.15%. That is 184.1 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −5.28.

Across the 3 fiscal years on file, revenue moves from $9.76M in 2023 to $18.62M in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 6.77 times revenue. On price-to-sales that is 55.63% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −70.72%. The stored price history starts on December 19, 2024, and the total return since then is −54.30%. Daily returns over the trailing 1 year annualize to a volatility of 100.26%.

Growth & Income

The record shows no dividend for RNA.

The record holds one complete calendar year, 2025, which returned +148.04%. 2026 is still running; the price is −80.33% year to date.

Peer Comparison

Atrium Therapeutics, Inc. (RNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Atrium Therapeutics, Inc. RNA $242.73M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Atrium Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Visit website →